Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 7/20 | 0.43 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12133256 | 0.94 | NQO2 (0.43) | NQO2MTNR1AMTNR1BKDM1AMAOA | |
| SCHEMBL13191560 | 0.93 | NQO2 (0.47) | NQO2MTNR1AMTNR1BKDM1AMAOA | |
| SCHEMBL12133264 | 0.89 | NQO2 (0.42) | NQO2MTNR1AMTNR1BMAOBSIGMAR1 | |
| SCHEMBL1346063 | 0.87 | NQO2 (0.48) | NQO2MTNR1AMTNR1BKDM1AMAOA | |
| SCHEMBL1346515 | 0.85 | DRD2 (0.44) | NQO2MTNR1AMTNR1BKDM1AMAOA | |
| SCHEMBL1346104 | 0.82 | NQO2 (0.41) | NQO2MTNR1AMTNR1BKDM1AMAOA | |
| SCHEMBL1346006 | 0.81 | SHBG (0.47) | SIGMAR1 | |
| SCHEMBL14655844 | 0.81 | NQO2 (0.43) | NQO2MTNR1AMTNR1BKDM1AMAOA | |
| SCHEMBL14489162 | 0.79 | NPY5R (0.45) | NQO2MTNR1AMTNR1BSIGMAR1HTR1A | |
| SCHEMBL605742 | 0.78 | HTR2A (0.45) | NQO2MTNR1AMTNR1BSIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406206-B1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | MSD OSS BV (NL) | 2013-01-30 | — | — | EP | disclosed |
| US-8063102-B2 | Tetrahydronaphthalen-2-ol derivatives | N.V. ORGANON (NL) | 2011-11-22 | — | — | US | disclosed |
| US-8063102-B2 | Tetrahydronaphthalen-2-ol derivatives | N.V. ORGANON (NL) | 2011-11-22 | — | — | US | disclosed |
| US-8063102-B2 | Tetrahydronaphthalen-2-ol derivatives | N.V. ORGANON (NL) | 2011-11-22 | — | — | US | disclosed |
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | N. V. ORGANON | 2010-09-23 | — | — | US | disclosed |
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | N. V. ORGANON | 2010-09-23 | — | — | US | disclosed |
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | N. V. ORGANON | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | VHL, BRCA1, TPH2 | NQO2 1888/4885MTNR1A 133/4885MTNR1B 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.